Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
Thyroid Cancer|Renal Cell Carcinoma|Non Small Cell Lung Cancer|Small-cell Lung Cancer|Bladder Cancer|Melanoma|Merkel Cell Carcinoma|Skin Squamous Cell Carcinoma|Microsatellite Instability High|Triple Negative Breast Cancer|Mesothelioma|Thymic Cancer|Cervical Cancer|Biliary Tract Cancer|Hepatocellular Carcinoma|Ovarian Cancer|Gastric Cancer|Head and Neck Squamous Cell Carcinoma|Anal Cancer
DRUG: Nanrilkefusp alfa|DRUG: Pembrolizumab
Part A: Number of participants with dose-limiting toxicities (DLTs), Adverse events (AEs) as per NCI CTCAE version 5.0:

* Grade 5 not related to disease progression or other causes
* Grade ≥3 non-hematologic toxicity; exceptions: grade 3 nausea, vomiting or diarrhea controlled in 72 hours; grade 3 fatigue \<5 days; grade ≥3 correctable electrolyte abnormalities \<72 hours and no clinical complications; grade ≥3 amylase or lipase without clinical pancreatitis
* Hy's law cases
* Grade 3 AST or ALT or grade 3 bilirubinemia \>5 days
* Hematologic DLTs:

  * Grade 4 neutropenia or thrombocytopenia \>7 days
  * Febrile neutropenia
  * Grade ≥3 thrombocytopenia with bleeding
* Grade 4 immune-related AEs
* Grade 3 or 4 non-infectious pneumonitis
* Grade 3 immune-related AEs, excluding colitis, hepatitis, and pneumonitis, not downgrading to grade ≤2 in 3 days despite maximal supportive care including systemic corticosteroids or to grade 1 or baseline in 14 days
* Grade 2 pneumonitis not downgrading to grade 1 in 3 days
* Grade 3 colitis, Through Cycle 1 (21 days)|Part A1: Number of participants with DLTs, AEs as per NCI CTCAE version 5.0:

* Grade 5 not related to disease progression or other causes
* Grade ≥3 non-hematologic toxicity; exceptions: grade 3 nausea, vomiting or diarrhea controlled in 72 hours; grade 3 fatigue \<5 days; grade ≥3 correctable electrolyte abnormalities \<72 hours and no clinical complications; grade ≥3 amylase or lipase without clinical pancreatitis
* Hy's law cases
* Grade 3 AST or ALT or grade 3 bilirubinemia \>5 days
* Hematologic DLTs:

  * Grade 4 neutropenia or thrombocytopenia \>7 days
  * Febrile neutropenia
  * Grade ≥3 thrombocytopenia with bleeding
* Grade 4 immune-related AEs
* Grade 3 or 4 non-infectious pneumonitis
* Grade 3 immune-related AEs, excluding colitis, hepatitis, and pneumonitis, not downgrading to grade ≤2 in 3 days despite maximal supportive care including systemic corticosteroids or to grade 1 or baseline in 14 days
* Grade 2 pneumonitis not downgrading to grade 1 in 3 days
* Grade 3 colitis, Through Cycle 1 (21 days)|Part B: Number of participants with DLTs, AEs as per NCI CTCAE version 5.0:

* Grade 5 not related to disease progression or other causes
* Grade ≥3 non-hematologic toxicity; exceptions: grade 3 nausea, vomiting or diarrhea controlled in 72 hours; grade 3 fatigue \<5 days; grade ≥3 correctable electrolyte abnormalities \<72 hours and no clinical complications; grade ≥3 amylase or lipase without clinical pancreatitis
* Hy's law cases
* Grade 3 AST or ALT or grade 3 bilirubinemia \>5 days
* Hematologic DLTs:

  * Grade 4 neutropenia or thrombocytopenia \>7 days
  * Febrile neutropenia
  * Grade ≥3 thrombocytopenia with bleeding
* Grade 4 immune-related AEs
* Grade 3 or 4 non-infectious pneumonitis
* Grade 3 immune-related AEs, excluding colitis, hepatitis, and pneumonitis, not downgrading to grade ≤2 in 3 days despite maximal supportive care including systemic corticosteroids or to grade 1 or baseline in 14 days
* Grade 2 pneumonitis not downgrading to grade 1 in 3 days
* Recurrent grade 2 pneumonitis
* Grade 3 colitis, Through Cycle 1 (21 days)|Part B1: Number of participants with DLTs, AEs as per NCI CTCAE version 5.0:

* Grade 5 not related to disease progression or other causes
* Grade ≥3 non-hematologic toxicity; exceptions: grade 3 nausea, vomiting or diarrhea controlled in 72 hours; grade 3 fatigue \<5 days; grade ≥3 correctable electrolyte abnormalities \<72 hours and no clinical complications; grade ≥3 amylase or lipase without clinical pancreatitis
* Hy's law cases
* Grade 3 AST or ALT or grade 3 bilirubinemia \>5 days
* Hematologic DLTs:

  * Grade 4 neutropenia or thrombocytopenia \>7 days
  * Febrile neutropenia
  * Grade ≥3 thrombocytopenia with bleeding
* Grade 4 immune-related AEs
* Grade 3 or 4 non-infectious pneumonitis
* Grade 3 immune-related AEs, excluding colitis, hepatitis, and pneumonitis, not downgrading to grade ≤2 in 3 days despite maximal supportive care including systemic corticosteroids or to grade 1 or baseline in 14 days
* Grade 2 pneumonitis not downgrading to grade 1 in 3 days
* Recurrent grade 2 pneumonitis
* Grade 3 colitis, Through Cycle 1 (21 days)|Part A: Number of participants with AEs, Nanrilkefusp alfa related only, Day 1 up to approximately 3 years|Part A1: Number of participants with AEs, Nanrilkefusp alfa related only, Day 1 up to approximately 3 years|Part B: Number of participants with AEs, Nanrilkefusp alfa related only, Day 1 up to approximately 3 years|Part B1: Number of participants with AEs, Nanrilkefusp alfa related only, Day 1 up to approximately 3 years|Part D: Number of participants with AEs, Nanrilkefusp alfa related only, Day 1 up to approximately 3 years|Part A: Number of participants with serious AEs (SAEs), Nanrilkefusp alfa related only, Day 1 up to approximately 3 years|Part A1: Number of participants with SAEs, Nanrilkefusp alfa related only, Day 1 up to approximately 3 years|Part B: Number of participants with SAEs, Nanrilkefusp alfa related only, Day 1 up to approximately 3 years|Part B1: Number of participants with SAEs, Nanrilkefusp alfa related only, Day 1 up to approximately 3 years|Part D: Number of participants with SAEs, Nanrilkefusp alfa related only, Day 1 up to approximately 3 years|Part A: Number of participants with AEs leading to premature discontinuation of nanrilkefusp alfa, Nanrilkefusp alfa related only, Day 1 up to approximately 3 years|Part A1: Number of participants with AEs leading to premature discontinuation of nanrilkefusp alfa, Nanrilkefusp alfa related only, Day 1 up to approximately 3 years|Part B: Number of participants with AEs leading to premature discontinuation of nanrilkefusp alfa, Nanrilkefusp alfa related only, Day 1 up to approximately 3 years|Part B1: Number of participants with AEs leading to premature discontinuation of nanrilkefusp alfa, Nanrilkefusp alfa related only, Day 1 up to approximately 3 years|Part D: Number of participants with AEs leading to premature discontinuation of nanrilkefusp alfa, Nanrilkefusp alfa related only, Day 1 up to approximately 3 years|Part A: Number of participants who died, Nanrilkefusp alfa-related deaths only, Day 1 up to approximately 3 years|Part A1: Number of participants who died, Nanrilkefusp alfa-related deaths only, Day 1 up to approximately 3 years|Part B: Number of participants who died, Nanrilkefusp alfa-related deaths only, Day 1 up to approximately 3 years|Part B1: Number of participants who died, Nanrilkefusp alfa-related deaths only, Day 1 up to approximately 3 years|Part D: Number of participants who died, Nanrilkefusp alfa-related deaths only, Day 1 up to approximately 3 years|Part A: Number of participants with nanrilkefusp alfa-related clinical laboratory test abnormalities (coagulation; hematology; clinical chemistry; urinalysis; thyroid and cardiac function), The following laboratory parameters will be assessed:

* Coagulation: Prothrombin time, activated partial thromboplastin time, international normalized ratio, D-dimer, fibrinogen
* Hematology: Hemoglobin, hematocrit, red blood cell count, reticulocytes, white blood cell count (with full differentiation), absolute lymphocyte count, platelet count
* Clinical chemistry: Na, K, Cl, phosphate, Mg, Ca, albumin, total protein, ALT, AST, bilirubin (direct, total), alkaline phosphatase, lactate dehydrogenase, creatinine clearance, creatinine, glucose (preferably fasting), urea or blood urea nitrogen, cholesterol, triglyceride, CRP, uric acid, amylase, lipase
* Urinalysis: pH, glucose, protein, bilirubin, urobilinogen. Microscopic examination: red blood cell count, white blood cell count, epithelial cells, bacteria
* Thyroid function: TSH, free triiodothyronine (T3), free thyroxine (T4)
* Cardiac function: Cardiac troponin T, Day 1 up to approximately 3 years|Part A1: Number of participants with nanrilkefusp alfa-related clinical laboratory test abnormalities (coagulation; hematology; clinical chemistry; urinalysis; thyroid and cardiac function), The following laboratory parameters will be assessed:

* Coagulation: Prothrombin time, activated partial thromboplastin time, international normalized ratio, D-dimer, fibrinogen
* Hematology: Hemoglobin, hematocrit, red blood cell count, reticulocytes, white blood cell count (with full differentiation), absolute lymphocyte count, platelet count
* Clinical chemistry: Na, K, Cl, phosphate, Mg, Ca, albumin, total protein, ALT, AST, bilirubin (direct, total), alkaline phosphatase, lactate dehydrogenase, creatinine clearance, creatinine, glucose (preferably fasting), urea or blood urea nitrogen, cholesterol, triglyceride, CRP, uric acid, amylase, lipase
* Urinalysis: pH, glucose, protein, bilirubin, urobilinogen. Microscopic examination: red blood cell count, white blood cell count, epithelial cells, bacteria
* Thyroid function: TSH, free triiodothyronine (T3), free thyroxine (T4)
* Cardiac function: Cardiac troponin T, Day 1 up to approximately 3 years|Part B: Number of participants with nanrilkefusp alfa-related clinical laboratory test abnormalities (coagulation; hematology; clinical chemistry; urinalysis; thyroid and cardiac function), The following laboratory parameters will be assessed:

* Coagulation: Prothrombin time, activated partial thromboplastin time, international normalized ratio, D-dimer, fibrinogen
* Hematology: Hemoglobin, hematocrit, red blood cell count, reticulocytes, white blood cell count (with full differentiation), absolute lymphocyte count, platelet count
* Clinical chemistry: Na, K, Cl, phosphate, Mg, Ca, albumin, total protein, ALT, AST, bilirubin (direct, total), alkaline phosphatase, lactate dehydrogenase, creatinine clearance, creatinine, glucose (preferably fasting), urea or blood urea nitrogen, cholesterol, triglyceride, CRP, uric acid, amylase, lipase
* Urinalysis: pH, glucose, protein, bilirubin, urobilinogen. Microscopic examination: red blood cell count, white blood cell count, epithelial cells, bacteria
* Thyroid function: TSH, free triiodothyronine (T3), free thyroxine (T4)
* Cardiac function: Cardiac troponin T, Day 1 up to approximately 3 years|Part B1: Number of participants with nanrilkefusp alfa-related clinical laboratory test abnormalities (coagulation; hematology; clinical chemistry; urinalysis; thyroid and cardiac function), The following laboratory parameters will be assessed:

* Coagulation: Prothrombin time, activated partial thromboplastin time, international normalized ratio, D-dimer, fibrinogen
* Hematology: Hemoglobin, hematocrit, red blood cell count, reticulocytes, white blood cell count (with full differentiation), absolute lymphocyte count, platelet count
* Clinical chemistry: Na, K, Cl, phosphate, Mg, Ca, albumin, total protein, ALT, AST, bilirubin (direct, total), alkaline phosphatase, lactate dehydrogenase, creatinine clearance, creatinine, glucose (preferably fasting), urea or blood urea nitrogen, cholesterol, triglyceride, CRP, uric acid, amylase, lipase
* Urinalysis: pH, glucose, protein, bilirubin, urobilinogen. Microscopic examination: red blood cell count, white blood cell count, epithelial cells, bacteria
* Thyroid function: TSH, free triiodothyronine (T3), free thyroxine (T4)
* Cardiac function: Cardiac troponin T, Day 1 up to approximately 3 years|Part D: Number of participants with nanrilkefusp alfa-related clinical laboratory test abnormalities (coagulation; hematology; clinical chemistry; urinalysis; thyroid and cardiac function), The following laboratory parameters will be assessed:

* Coagulation: Prothrombin time, activated partial thromboplastin time, international normalized ratio, D-dimer, fibrinogen
* Hematology: Hemoglobin, hematocrit, red blood cell count, reticulocytes, white blood cell count (with full differentiation), absolute lymphocyte count, platelet count
* Clinical chemistry: Na, K, Cl, phosphate, Mg, Ca, albumin, total protein, ALT, AST, bilirubin (direct, total), alkaline phosphatase, lactate dehydrogenase, creatinine clearance, creatinine, glucose (preferably fasting), urea or blood urea nitrogen, cholesterol, triglyceride, CRP, uric acid, amylase, lipase
* Urinalysis: pH, glucose, protein, bilirubin, urobilinogen. Microscopic examination: red blood cell count, white blood cell count, epithelial cells, bacteria
* Thyroid function: TSH, free triiodothyronine (T3), free thyroxine (T4)
* Cardiac function: Cardiac troponin T, Day 1 up to approximately 3 years
Part A: Nanrilkefusp alfa concentration profile, Cycle 1 Day 1, 1 hour (+/-15 minutes), After 12 μg/kg nanrilkefusp alfa administration, Cycle 1 Day 1, 1 hour (+/-15 minutes)|Part A1: Nanrilkefusp alfa concentration profile, Cycle 1 Day 1, 1 hour (+/-15 minutes), After 12 μg/kg nanrilkefusp alfa administration, Cycle 1 Day 1, 1 hour (+/-15 minutes)|Part B: Nanrilkefusp alfa concentration profile, Cycle 1 Day 1, 1 hour (+/-15 minutes), After 12 μg/kg nanrilkefusp alfa administration, Cycle 1 Day 1, 1 hour (+/-15 minutes)|Part D: Nanrilkefusp alfa concentration profile, Cycle 1 Day 1, 1 hour (+/-15 minutes), After 12 μg/kg nanrilkefusp alfa administration, Cycle 1 Day 1, 1 hour (+/-15 minutes)|Part A: Nanrilkefusp alfa concentration profile, Cycle 1 Day 1, 4 hours (+/-15 minutes), After 12 μg/kg nanrilkefusp alfa administration, Cycle 1 Day 1, 4 hours (+/-15 minutes)|Part A1: Nanrilkefusp alfa concentration profile, Cycle 1 Day 1, 4 hours (+/-15 minutes), After 12 μg/kg nanrilkefusp alfa administration, Cycle 1 Day 1, 4 hours (+/-15 minutes)|Part B: Nanrilkefusp alfa concentration profile, Cycle 1 Day 1, 4 hours (+/-15 minutes), After 12 μg/kg nanrilkefusp alfa administration, Cycle 1 Day 1, 4 hours (+/-15 minutes)|Part D: Nanrilkefusp alfa concentration profile, Cycle 1 Day 1, 4 hours (+/-15 minutes), After 12 μg/kg nanrilkefusp alfa administration, Cycle 1 Day 1, 4 hours (+/-15 minutes)|Part A: Overall activation levels of Ki-67+ CD8+ T cells on day 6 of cycle 1, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part A1: Overall activation levels of Ki-67+ CD8+ T cells on day 6 of cycle 1, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part B: Overall activation levels of Ki-67+ CD8+ T cells on day 6 of cycle 1, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part D: Overall activation levels of Ki-67+ CD8+ T cells on day 6 of cycle 1, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part A: Overall activation levels of Ki-67+ CD8+ CD45RO+ CD45RA- T cells on day 6 of cycle 1, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part A1: Overall activation levels of Ki-67+ CD8+ CD45RO+ CD45RA- T cells on day 6 of cycle 1, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part B: Overall activation levels of Ki-67+ CD8+ CD45RO+ CD45RA- T cells on day 6 of cycle 1, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part D: Overall activation levels of Ki-67+ CD8+ CD45RO+ CD45RA- T cells on day 6 of cycle 1, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part A: Overall activation levels of Ki-67+ CD4+ T cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part A1: Overall activation levels of Ki-67+ CD4+ T cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part B: Overall activation levels of Ki-67+ CD4+ T cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part D: Overall activation levels of Ki-67+ CD4+ T cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part A: Overall activation levels of Ki-67+ NK cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part A1: Overall activation levels of Ki-67+ NK cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part B: Overall activation levels of Ki-67+ NK cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part D: Overall activation levels of Ki-67+ NK cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part A: Overall activation levels of Ki-67+ NKT cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part A1: Overall activation levels of Ki-67+ NKT cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part B: Overall activation levels of Ki-67+ NKT cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part D: Overall activation levels of Ki-67+ NKT cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part A: Overall activation levels of Ki-67+ Treg cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part A1: Overall activation levels of Ki-67+ Treg cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part B: Overall activation levels of Ki-67+ Treg cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part D: Overall activation levels of Ki-67+ Treg cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa, At 12 μg/kg nanrilkefusp alfa, Day 6 of Cycle 1|Part A: Objective response rate (ORR), Based on investigator review of radiographic images according to Response Evaluation Criteria In Solid Tumors for immune-based therapeutics (iRECIST), Day 1 up to approximately 3 years|Part A1: ORR, Based on investigator review of radiographic images according to iRECIST, Day 1 up to approximately 3 years|Part B: ORR, Based on investigator review of radiographic images according to iRECIST, Day 1 up to approximately 3 years|Part D: ORR, Based on investigator review of radiographic images according to iRECIST, Day 1 up to approximately 3 years|Part A: Duration of response (DoR), DoR according to iRECIST, Day 1 up to approximately 3 years|Part A1: DoR, DoR according to iRECIST, Day 1 up to approximately 3 years|Part B: DoR, DoR according to iRECIST, Day 1 up to approximately 3 years|Part D: DoR, DoR according to iRECIST, Day 1 up to approximately 3 years|Part A: Clinical benefit rate (CBR), CBR according to iRECIST, Day 1 up to approximately 3 years|Part A1: CBR, CBR according to iRECIST, Day 1 up to approximately 3 years|Part B: CBR, CBR according to iRECIST, Day 1 up to approximately 3 years|Part D: CBR, CBR according to iRECIST, Day 1 up to approximately 3 years|Part A: Progression-free survival (PFS), PFS according to iRECIST, Day 1 up to approximately 3 years|Part A1: PFS, PFS according to iRECIST, Day 1 up to approximately 3 years|Part B: PFS, PFS according to iRECIST, Day 1 up to approximately 3 years|Part D: PFS, PFS according to iRECIST, Day 1 up to approximately 3 years|Part A: Number of participants with anti-drug antibodies (ADAs) at the end of treatment, Against nanrilkefusp alfa, End of treatment with nanrilkefusp alfa|Part A1: Number of participants with ADAs at the end of treatment, Against nanrilkefusp alfa, End of treatment with nanrilkefusp alfa|Part B: Number of participants with ADAs at the end of treatment, Against nanrilkefusp alfa, End of treatment with nanrilkefusp alfa|Part B1: Number of participants with ADAs at the end of treatment, Against nanrilkefusp alfa, End of treatment with nanrilkefusp alfa|Part D: Number of participants with ADAs at the end of treatment, Against nanrilkefusp alfa, End of treatment with nanrilkefusp alfa
This study will assess the safety and tolerability of nanrilkefusp alfa administered as monotherapy and in combination with an anti-PD-1 antibody (pembrolizumab) in patients with selected relapsed/refractory advanced/metastatic solid tumors (renal cell carcinoma, non-small cell lung cancer, small-cell lung cancer, bladder cancer, melanoma, Merkel-cell carcinoma, skin squamous-cell carcinoma, microsatellite instability high solid tumors, triple-negative breast cancer, mesothelioma, thyroid cancer, thymic cancer, cervical cancer, biliary tract cancer, hepatocellular carcinoma, ovarian cancer, gastric cancer, head and neck squamous-cell carcinoma, and anal cancer).